Along with funding from the United States government and ten large pharmaceutical companies, the National Institutes of Health (NIH), Bethesda, Maryland will split the cost of a new multimillion project targeting common chronic human diseases.
The companies involved include Pfizer Inc., Eli Lilly & Co, AbbVie Inc., Biogen Idec Inc., Bristol-Myers Squibb Co., Glaxo Smith Kline Plc, Johnson & Johnson, Sanofi and Takeda Pharmaceutical Co. It was announced that data collected from this project will be made public for other scientists to use.
The major goal of this groundbreaking partnership, as specified by NIH’s officials, is to develop new therapeutic approaches and search for common ‘biomarkers’. This may suggest new targets for drugs to treat Alzheimer’s disease, diabetes, lupus erythematosus and arthritis, diseases that are among the most common conditions in the US and worldwide.
As per bloomberg more than 5 million Americans suffer with Alzheimer’s disease, and the number is expected to triple by 2050. The $230 million project may be particularly important for Alzheimer’s research, as in the last two decades there have been more than 100 attempts to develop a treatment, and all have failed.
According to the NIH’s Director Francis Collins “we are going to try to increase the odds of picking the right targets to go after for the next generation of drug development”. He also stated that “we want to pick them at the very beginning of the development process and thus avoid wasting precious time and money chasing down drugs.”
Read More: bloomberg.com
Related stories you may like: Aducanumab Shows Promise and Impressive Effects in Reducing Alzheimer’s Amyloid-β Plaques
Blocking IL-12 and IL-23 in APPPS1 Mouse Model Shows Promise as an Experimental Therapeutic Approach to Alzheimer’s Disease
Interleukin-33 Reverses Cognitive Deficits in Alzheimer’s Mouse Model Showing Promise as a Therapeutic Target